GSK-2126458 25 mg | ≥99% LKT Laboratories, Inc. p110α PI3K and mTOR inhibitor. More Information Supplier Page × GSK-2126458
GSK-2126458 5 mg | ≥99% LKT Laboratories, Inc. p110α PI3K and mTOR inhibitor. More Information Supplier Page × GSK-2126458
GSK-2126458 1 mg | ≥99% LKT Laboratories, Inc. p110α PI3K and mTOR inhibitor. More Information Supplier Page × GSK-2126458
LDK378 25 mg | ≥99% LKT Laboratories, Inc. ALK and IGF-1R inhibitor. More Information Supplier Page × LDK378
Escitalopram Oxalate 10 mg | ≥99% LKT Laboratories, Inc. S-enantiomer of citalopram; SERT inhibitor. More Information Supplier Page × Escitalopram Oxalate
Regorafenib Monohydrate 25 mg | ≥99% LKT Laboratories, Inc. VEGFR1/2/3, TIE2, PDGFRβ, FGFR1, c-Kit, RET, B-Raf inhibitor. More Information Supplier Page × Regorafenib Monohydrate
Regorafenib Monohydrate 5 mg | ≥99% LKT Laboratories, Inc. VEGFR1/2/3, TIE2, PDGFRβ, FGFR1, c-Kit, RET, B-Raf inhibitor. More Information Supplier Page × Regorafenib Monohydrate
